Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
NCT03382899 · Eli Lilly and Company · PHASE2 · terminated · last registry update 2021-01-20 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The CYPRESS-1 trial was closed early after the planned primary analysis because the risk benefit ratio is unfavorable.” | Open Targets' class: negative, safety sideeffects | Registry record, Eli Lilly and Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL10RB in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision